25.75
-0.14 (-0.54%)
| Previous Close | 25.89 |
| Open | 26.01 |
| Volume | 5,158,198 |
| Avg. Volume (3M) | 3,266,657 |
| Market Cap | 3,714,238,464 |
| Price / Sales | 47.99 |
| Price / Book | 10.74 |
| 52 Weeks Range | |
| Earnings Date | 11 May 2026 |
| Operating Margin (TTM) | -788.76% |
| Diluted EPS (TTM) | -1.20 |
| Quarterly Revenue Growth (YOY) | -16.70% |
| Total Debt/Equity (MRQ) | 22.16% |
| Current Ratio (MRQ) | 6.26 |
| Operating Cash Flow (TTM) | -135.34 M |
| Levered Free Cash Flow (TTM) | -67.25 M |
| Return on Assets (TTM) | -26.79% |
| Return on Equity (TTM) | -61.35% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Tango Therapeutics, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | -1.5 |
| Insider Activity | -3.0 |
| Price Volatility | -3.0 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | 4.0 |
| Average | -0.90 |
|
Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 12.59% |
| % Held by Institutions | 97.41% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Farallon Capital Management Llc | 31 Dec 2025 | 13,061,411 |
| Boxer Capital Management, Llc | 31 Dec 2025 | 10,876,219 |
| Woodline Partners Lp | 31 Dec 2025 | 10,072,225 |
| Trv Gp Iv, Llc | 31 Dec 2025 | 7,874,574 |
| Nextech Invest, Ltd. | 31 Dec 2025 | 7,266,081 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 27.00 (HC Wainwright & Co., 4.85%) | Buy |
| Median | 20.00 (-22.33%) | |
| Low | 19.00 (Wedbush, -26.21%) | Buy |
| Average | 22.00 (-14.56%) | |
| Total | 5 Buy | |
| Avg. Price @ Call | 16.86 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Mizuho | 11 Mar 2026 | 20.00 (-22.33%) | Buy | 16.99 |
| 23 Feb 2026 | 19.00 (-26.21%) | Buy | 12.73 | |
| Stifel | 09 Mar 2026 | 24.00 (-6.80%) | Buy | 16.45 |
| Guggenheim | 06 Mar 2026 | 20.00 (-22.33%) | Buy | 16.95 |
| 06 Feb 2026 | 18.00 (-30.10%) | Buy | 12.51 | |
| HC Wainwright & Co. | 06 Mar 2026 | 27.00 (4.85%) | Buy | 16.95 |
| Wedbush | 06 Mar 2026 | 19.00 (-26.21%) | Buy | 16.95 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| CRYSTAL ADAM | - | 25.33 | -38,460 | -974,192 |
| Aggregate Net Quantity | -38,460 | |||
| Aggregate Net Value ($) | -974,192 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 25.33 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| CRYSTAL ADAM | Officer | 15 Apr 2026 | Automatic sell (-) | 38,460 | 25.33 | 974,192 |
| CRYSTAL ADAM | Officer | 15 Apr 2026 | Option execute | 38,460 | - | - |
| Date | Type | Details |
|---|---|---|
| 03 Feb 2026 | Announcement | Tango Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |